Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
about
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseaseReview of meningococcal vaccines with updates on immunization in adultsDevelopment and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Routinely vaccinating adolescents against meningococcus: targeting transmission & diseasePersistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infantsPersistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.Glycoconjugate vaccines: an update.Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.Fighting Neisseria meningitidis: past and current vaccination strategies.Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
P2860
Q27028161-96F4AAC2-2CFB-4ACA-BBA7-FF1807F59753Q28828692-AED4659F-0C67-4443-A1E1-7D2655FC4A41Q33601899-605600AA-0E60-49E1-847C-69337B51C919Q35799561-20DC81BF-7EDB-45AB-8F63-DD27E92C2028Q36825737-4CA0BBF2-E37E-4A4A-B258-38591721969AQ37131083-B41F0491-E32C-402A-BAAA-69E11B1AEB55Q37197065-704E2E0C-9447-4FEB-A751-CCA96B9AD7F2Q37713775-3D62F0D9-0D6C-4DA9-9D59-3B606F4176A4Q38109830-2B15FA61-E1C1-4742-B2A3-3C45229B7869Q38286346-672E57D8-E4A2-465C-9FB4-D77126207307Q38743826-CAF38573-0EA3-408F-8020-DADE535572B8Q38829564-972DE117-E24E-42A0-970C-D5BA3CEEA98BQ38944335-A3FD73D6-CB0B-4D2F-8CC1-943C552DDEE7
P2860
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immune response, antibody pers ...... randomised, controlled study.
@ast
Immune response, antibody pers ...... randomised, controlled study.
@en
Immune response, antibody pers ...... randomised, controlled study.
@nl
type
label
Immune response, antibody pers ...... randomised, controlled study.
@ast
Immune response, antibody pers ...... randomised, controlled study.
@en
Immune response, antibody pers ...... randomised, controlled study.
@nl
prefLabel
Immune response, antibody pers ...... randomised, controlled study.
@ast
Immune response, antibody pers ...... randomised, controlled study.
@en
Immune response, antibody pers ...... randomised, controlled study.
@nl
P2093
P2860
P356
P1476
Immune response, antibody pers ...... randomised, controlled study.
@en
P2093
Cecilia Montalban
Charissa Borja-Tabora
Dominique Boutriau
Jacqueline Miller
Marie Van der Wielen
Veronique Bianco
P2860
P2888
P356
10.1186/1471-2334-13-116
P577
2013-03-05T00:00:00Z
P5875
P6179
1009938080